Background: Sunitinib has been approved for the treatment of metastatic renal cell carcinoma (RCC) as the first-line therapy. However, the patients treated with sunitinib have a high frequency of severe toxicities, and require dose reduction and discontinuation. In additon, limited data are available for special populations (e.g. hemodialyzed patients). To overcome these clinical problems, pharmacokinetic (PK), pharmacodynamic (PD) and pharmacogenomic (PGx) approaches might contribute to optimal dose adjustment for sunitinib. Methods: We evaluated the association trough sunitinib concentration during the first cycle with clinical outcomes and its toxicities for RCC patients (n ¼ 21). Side effects were evaluated using the CTCAE v4.0. Progression-free survival (PFS) was estimated
using the Kaplane-Meier method. We also investigated the PK of sunitinib in a hemodialyzed patient. Results: The median sunitinib concentration was 91.8 ng/mL (range, 49.8-205 ng/mL). Patients with !100 ng/mL total sunitinib (n ¼ 8), compared with patients with <100 ng/mL (n ¼ 13), had a greater incidence of Grade !3 toxicities (75.0% vs. 23.1%). Patients with <100 ng/mL sunitinib had significantly longer PFS time than patients with !100 ng/mL (median PFS, 748 vs. 238 days; P¼.02). Among them, 1 patient had extremely higher exposure to sunitinib (205 ng/mL), who had the rare genetic polymorphisms of ABC transporters as follow: homozygosity for ABCG2 34G<A and the ABCB1 1236-2677-3435 TTT haplotype. The PK of sunitinib was shown to be not affected by hemodialysis. Conclusion: Results of this study suggest that PK/PD/PGx analysis of sunitinib could be useful for avoiding severe toxicities. Especially, PK data of sunitinb shows that !100 ng/mL sunitinib might be a limiting factor leading to treatment discontinuation. We indicated that sunitinib can become treatment options for hemodialyzed patients. 
